FORM 4

Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b).

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHANGES IN BENEFICIAL O	OWNERSHIP
------------------------------------------------------------------------	--------------------------------------	-----------

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  GOLDSTEIN DOV A MD				2. Issuer Name and Ticker or Trading Symbol ADMA BIOLOGICS, INC. [ NONE ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
									_	_		X	Directo	or		10% Ov	ner	
(Last) (First) (Middle)				3. Date of Earliest Transaction (Month/Day/Year) 04/04/2012									Officer below)	(give title		Other (s below)	pecify	
888 SEVENTH AVENUE																		
30TH FLOOR				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable					
(Street)													Line)	Form fi	iled by One	Dono	rtina Doroo	,
NEW YO	ORK N	Y	10106										Λ		led by More		•	
(City)	(S	tate)	(Zip)															
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
Date			Transactio ate Ionth/Day/\	Execution Date,		Transaction Disposed Code (Instr. 5)			ties Acquired (A) o d Of (D) (Instr. 3, 4			5. Amour Securitie Beneficia Owned F	s ally following	Form:	Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
							Code	Code V Amount (A)		(A) (D)	Pr	ice	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Yo	ate, Transaction Code (Instr.		n of		5. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amour of Securities Underlying Derivative Securit (Instr. 3 and 4)		[	3. Price of Derivative Security Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)		Date Exercisable		xpiration ate	Title	Amo or Num of Shar	ber					
Stock Option	\$9.6	04/04/2012		A		13,258		(1)	04	4/03/2022	Common Stock	13,2	258	\$0	13,258		D <sup>(2)</sup>	

## **Explanation of Responses:**

- 1. 25% of these options will become exercisable on April 4, 2013, and the remainder will become exercisable in equal monthly installments on the 29th of each month until April 4, 2016.
- 2. These stock options are held by Dr. Goldstein for the benefit of Aisling Capital LLC. Dr. Goldstein disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

/s/ Dov A. Goldstein

04/05/2012

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.